

Special Issue

Amyloid Beta: New Rational Structure-Based Therapeutic Development

Message from the Guest Editors

Until now, not all the failed clinical programs provided unquestionable proof of the amyloid hypothesis, and three main critical issues for amyloid-targeted therapies appeared: i) The lack of deep knowledge of what in the pathogenic form of amyloid should be inhibited or removed to stop the disease progression; ii) The importance of a correct brain concentration of the therapeutic agent, which is sufficient to elicit the desired biological response; iii) The need for adequate diagnostic tools that enable the optimal study population to be enrolled in terms of relevance and the stage of the disease that best assesses efficacy. In this Special Issue, we wish to focus on the design, synthesis, and application of new rational structure-based modulators of amyloid beta for successful therapies against neurodegenerative diseases. Research articles, comprehensive reviews, and short communications are welcome to collect the most recent insights and results in therapeutic innovation involving multidisciplinary approaches and addressing various pharmacological issues.

Guest Editors

Dr. Nicolo Tonali

BioCIS, Université Paris-Saclay, Faculté de Pharmacie, 91400 Paris, France

Dr. Lidia Ciccone

Department of Pharmacy, University of Pisa, Via Bonanno 6, 56126 Pisa, Italy

Deadline for manuscript submissions

closed (30 August 2024)



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/166081

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)